Menu
GeneBe

ELANE

elastase, neutrophil expressed, the group of Granule associated serine proteases of immune defence|Complement system regulators and receptors

Basic information

Region (hg38): 19:851013-856247

Previous symbols: [ "ELA2" ]

Links

ENSG00000197561NCBI:1991OMIM:130130HGNC:3309Uniprot:P08246AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • autosomal dominant severe congenital neutropenia (Supportive), mode of inheritance: AD
  • cyclic hematopoiesis (Supportive), mode of inheritance: AD
  • cyclic hematopoiesis (Strong), mode of inheritance: AD
  • neutropenia (Definitive), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Neutropenia, severe congenital 1, autosomal dominant; Neutropenia, cyclicADAllergy/Immunology/Infectious; OncologicAntiinfectious prophylaxis (including GCSF and related therapies) and early and aggressive treatment of infections may be beneficial; Surveillance and early treatment for malignancy may be beneficial; HSCT has been described for severe congenital neutropeniaAllergy/Immunology/Infectious; Oncologic13575153; 6050865; 4319697; 2471075; 2469956; 1282277; 8490166; 7529539; 8541539; 8989458; 8624368; 9116280; 9386665; 10581030; 11001877; 10887102; 17063141; 18028488; 17133096; 18611981; 19036076; 21072829; 22148006; 22080845; 22510773; 22624626; 22758217; 23454784; 23463630

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the ELANE gene.

  • Neutropenia, severe congenital, 1, autosomal dominant;Cyclical neutropenia (163 variants)
  • Cyclical neutropenia;Neutropenia, severe congenital, 1, autosomal dominant (146 variants)
  • not provided (144 variants)
  • not specified (42 variants)
  • Autoinflammatory syndrome (38 variants)
  • Cyclical neutropenia (22 variants)
  • Neutropenia, severe congenital, 1, autosomal dominant (17 variants)
  • Inborn genetic diseases (14 variants)
  • ELANE-related condition (9 variants)
  • - (2 variants)
  • Neutropenia (2 variants)
  • Hereditary angioedema with normal C1Inh (1 variants)
  • X-linked severe congenital neutropenia (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the ELANE gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
10
clinvar
69
clinvar
7
clinvar
86
missense
14
clinvar
34
clinvar
158
clinvar
10
clinvar
1
clinvar
217
nonsense
1
clinvar
1
clinvar
2
clinvar
4
start loss
2
clinvar
2
frameshift
4
clinvar
2
clinvar
6
clinvar
12
inframe indel
2
clinvar
1
clinvar
6
clinvar
9
splice donor/acceptor (+/-2bp)
2
clinvar
1
clinvar
4
clinvar
7
splice region
3
4
10
17
non coding
1
clinvar
23
clinvar
26
clinvar
50
Total 25 39 187 102 34

Highest pathogenic variant AF is 0.0000131

Variants in ELANE

This is a list of pathogenic ClinVar variants found in the ELANE region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
19-851457-A-G ELANE-related disorder Likely benign (Jun 20, 2022)3030858
19-851482-T-C ELANE-related disorder Likely benign (Feb 15, 2022)3057191
19-851976-G-A Benign (Jun 14, 2018)667820
19-852033-T-C Benign (Aug 30, 2018)1278686
19-852044-C-T Benign (Jun 26, 2018)1274055
19-852104-C-A Benign (Jun 19, 2018)677093
19-852167-C-T Likely benign (Jun 19, 2018)678420
19-852196-C-T Benign (Mar 03, 2015)1250740
19-852205-C-T Benign (Mar 03, 2015)1255032
19-852234-C-T Benign (Mar 03, 2015)1241499
19-852238-C-G Benign (Mar 03, 2015)1243625
19-852285-G-C Benign (Mar 03, 2015)1297304
19-852287-G-A Benign (Mar 03, 2015)1268417
19-852288-C-A not specified • Neutropenia, severe congenital, 1, autosomal dominant;Cyclical neutropenia Benign (Sep 27, 2023)137203
19-852288-C-T Benign (Mar 03, 2015)1236936
19-852318-C-T Benign (Mar 03, 2015)1297299
19-852324-C-T ELANE-related disorder Likely benign (Sep 23, 2020)3032788
19-852329-A-G Cyclical neutropenia;Neutropenia, severe congenital, 1, autosomal dominant Pathogenic (Nov 17, 2021)1343367
19-852330-T-C Pathogenic (Feb 23, 2018)988327
19-852337-C-T Cyclical neutropenia;Neutropenia, severe congenital, 1, autosomal dominant Likely benign (May 21, 2018)705531
19-852338-G-A Neutropenia, severe congenital, 1, autosomal dominant • Cyclical neutropenia;Neutropenia, severe congenital, 1, autosomal dominant Uncertain significance (Dec 14, 2023)570477
19-852338-G-C ELANE-related disorder Uncertain significance (Nov 24, 2022)2635364
19-852338-G-GGCC Cyclical neutropenia;Neutropenia, severe congenital, 1, autosomal dominant Uncertain significance (Jun 22, 2023)567638
19-852341-C-T Autoinflammatory syndrome Uncertain significance (Dec 04, 2020)1694265
19-852342-G-A Cyclical neutropenia;Neutropenia, severe congenital, 1, autosomal dominant Uncertain significance (Jan 12, 2024)661641

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
ELANEprotein_codingprotein_codingENST00000590230 55229
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.001230.8611255330201255530.0000797
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.7181641920.8540.00001501664
Missense in Polyphen3965.860.59216647
Synonymous-0.1709592.91.020.00000823597
Loss of Function1.28610.50.5727.15e-782

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.00007580.0000616
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.0004920.000277
European (Non-Finnish)0.00006620.0000617
Middle Eastern0.000.00
South Asian0.0001990.000196
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Modifies the functions of natural killer cells, monocytes and granulocytes. Inhibits C5a-dependent neutrophil enzyme release and chemotaxis. {ECO:0000269|PubMed:15140022}.;
Disease
DISEASE: Neutropenia, severe congenital 1, autosomal dominant (SCN1) [MIM:202700]: A disorder of hematopoiesis characterized by maturation arrest of granulopoiesis at the level of promyelocytes with peripheral blood absolute neutrophil counts below 0.5 x 10(9)/l and early onset of severe bacterial infections. {ECO:0000269|PubMed:11001877, ECO:0000269|PubMed:11675333, ECO:0000269|PubMed:12091371, ECO:0000269|PubMed:14962902, ECO:0000269|PubMed:17436313, ECO:0000269|PubMed:18946670, ECO:0000269|PubMed:19036076, ECO:0000269|PubMed:19415009, ECO:0000269|PubMed:19927291, ECO:0000269|PubMed:20220065, ECO:0000269|PubMed:20803142, ECO:0000269|PubMed:21425445, ECO:0000269|PubMed:23463630}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Systemic lupus erythematosus - Homo sapiens (human);Transcriptional misregulation in cancer - Homo sapiens (human);Human Complement System;Neutrophil degranulation;Collagen degradation;Extracellular matrix organization;Antimicrobial peptides;Innate Immune System;Immune System;Activation of Matrix Metalloproteinases;Degradation of the extracellular matrix;Regulation of Complement cascade;C-MYB transcription factor network;Complement cascade;Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling (Consensus)

Recessive Scores

pRec
0.916

Intolerance Scores

loftool
0.0124
rvis_EVS
0.19
rvis_percentile_EVS
67.03

Haploinsufficiency Scores

pHI
0.609
hipred
Y
hipred_score
0.594
ghis

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
gene_indispensability_pred
E
gene_indispensability_score
0.698

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Elane
Phenotype
homeostasis/metabolism phenotype; neoplasm; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; immune system phenotype;

Gene ontology

Biological process
negative regulation of transcription by RNA polymerase II;response to yeast;acute inflammatory response to antigenic stimulus;leukocyte migration involved in inflammatory response;biosynthetic process of antibacterial peptides active against Gram-negative bacteria;proteolysis;cellular calcium ion homeostasis;phagocytosis;response to UV;antimicrobial humoral response;extracellular matrix disassembly;protein catabolic process;response to lipopolysaccharide;defense response to bacterium;neutrophil degranulation;positive regulation of MAP kinase activity;negative regulation of growth of symbiont in host;negative regulation of chemokine biosynthetic process;negative regulation of interleukin-8 biosynthetic process;positive regulation of interleukin-8 biosynthetic process;positive regulation of smooth muscle cell proliferation;negative regulation of inflammatory response;positive regulation of immune response;negative regulation of chemotaxis;neutrophil mediated killing of gram-negative bacterium;neutrophil mediated killing of fungus;positive regulation of leukocyte tethering or rolling
Cellular component
extracellular region;extracellular space;cytoplasm;cell surface;transcriptional repressor complex;secretory granule;azurophil granule lumen;specific granule lumen;collagen-containing extracellular matrix;extracellular exosome
Molecular function
protease binding;transcription corepressor activity;endopeptidase activity;serine-type endopeptidase activity;protein binding;heparin binding;peptidase activity;cytokine binding